Benitec Biopharma Inc. (BNTC)
NASDAQ: BNTC · Real-Time Price · USD
12.61
+0.53 (4.39%)
At close: Jan 29, 2026, 4:00 PM EST
12.61
0.00 (0.00%)
After-hours: Jan 29, 2026, 4:04 PM EST
Benitec Biopharma Employees
Benitec Biopharma had 19 employees as of June 30, 2025. The number of employees increased by 3 or 18.75% compared to the previous year.
Employees
19
Change (1Y)
3
Growth (1Y)
18.75%
Revenue / Employee
n/a
Profits / Employee
-$2,201,211
Market Cap
427.00M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 19 | 3 | 18.75% |
| Jun 30, 2024 | 16 | -2 | -11.11% |
| Jun 30, 2023 | 18 | 0 | - |
| Jun 30, 2022 | 18 | 4 | 28.57% |
| Jun 30, 2021 | 14 | 0 | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Rocket Pharmaceuticals | 299 |
| Entrada Therapeutics | 183 |
| Absci | 157 |
| Lineage Cell Therapeutics | 77 |
| Assembly Biosciences | 73 |
| Aclaris Therapeutics | 64 |
| Eupraxia Pharmaceuticals | 33 |
| Zura Bio | 30 |
BNTC News
- 18 days ago - Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response - GlobeNewsWire
- 2 months ago - Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update - GlobeNewsWire
- 3 months ago - Benitec Biopharma Inc. Announces Pricing of $100 Million Common Stock Offering - GlobeNewsWire
- 3 months ago - Benitec Biopharma Inc. Announces Proposed Public Offering - GlobeNewsWire
- 3 months ago - Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301 - GlobeNewsWire
- 3 months ago - Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy - GlobeNewsWire
- 4 months ago - Benitec Biopharma Releases Full Year 2025 Financial Results and Provides Operational Update - GlobeNewsWire
- 10 months ago - Benitec Biopharma: An Under-The-Radar And Undervalued Gene Therapy Developer - Seeking Alpha